Livzon Group announced that it signed the "Patent and Technology Transfer Agreement" with Shanghai Synergy Pharmaceutical Sciences Co., Ltd. on July 19, 2023. According to the agreement, Synergy Pharmaceutical Sciences agreed to transfer and transfer all the rights, ownership, and interests of the HHT120 project developed by it in Greater China to the company. Livzon Group needs to pay corresponding patent and technology transfer fees (including down payment, development milestone gold) and sales commission to Synergy Pharmaceutical Sciences. HHT120 is a thrombin inhibitor independently developed by Synergy Pharmaceutical Sciences. It has been approved by the National Medical Products Administration to carry out clinical trials in April 2022. The first clinical trial indication is planned to be used for preventing venous thrombosis after a major orthopedic surgery embolism.

From Weizhishu

July 21st, 2023